Australia's most trusted
source of pharma news
Friday, 05 July 2024
Posted 3 July 2024 AM
The TGA's decision on two highly anticipated medicines appears right around the corner after Europe's advisory committee, the CHMP, gave the green light last week.
MSD's Winrevair which has been under the TGA's review since March was recommended for approval by the CHMP for the treatment of adults with pulmonary arterial hypertension (PAH), in combination with other specific PAH therapies, to improve exercise capacity.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.